АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

Перечень основных медикаментов. § Спиронолактон, хлортиазид, фуросемид, дексаметазон, витамин А, сальбутамол

§ Спиронолактон, хлортиазид, фуросемид, дексаметазон, витамин А, сальбутамол

Перечень дополнительных медикаментов

§ Препараты для парентерального питания, антибактериальная терапия по показаниям.

Критерии эффективности лечения

§ Купирование признаков дыхательной недостаточности

Критерии выписки

§ если возраст ребенка позволяет, провести пассивную иммунизацию против респираторно – синцитиального вируса

§ организовать наблюдение за неврологическим развитием и респираторным статусом ребенка.

Список использованной литературы

1. Northway-WH Jr; Rosan-RC; Porter-DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276: 357-68.

2. Shennan-AT; Dunn-MS; Ohlsson-A; Lennox-K; Hoskins-EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988; 82: 527-32.

3. Vigneswaran R. Infection and preterm birth: evidence of a common causal relationship with bronchopulmonary dysplasia and cerebral palsy. J Paediatr Child Health. 2000; 36: 293-6

4. Jobe AH, Ikegami M. Antenatal infection/inflammation and postnatal lung maturation and injury. Respir Res, 2001; 2: 27-32.

5. Maxwell NC, Davies PL, Kotecha S. Antenatal infection and inflammation: what’s new? Curr Opin Infect Dis. 2006; 19: 253-258.

6. Hagberg H, Wennerholm U-B, Savman K. Sequelae of chorioamnionitis. Curr Opin Infect Dis. 2002; 15: 301-306.

7. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis, and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1997; 97: 210-15.

8. Fujimura M, Takeuchi T, Kitajima H, Nakayama M. Chorioamnionitis and serum IgM in Wilson-Mikity Syndrome. Arch Dis Child 1989; 64: 1379-1383.

9. Matsuda T, Nakajima T, Hattori S et al. Necrotising funisitis: Clinical significance and association with chronic lung disease in premature infants. Am J Obstet. Gynecol. 1997; 177: 1402-7.

10. Andrews WW, Goldenberg RL, Faye-Pederson O. et al. The Alabama Preterm Birth Study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23 to 32 week preterm newborn infants. Am J Obstet Gynecol 2006; 195: 803-8.

11. Dempsey E, Chen M-F, Kokottis T, et al. Outcome of neonates less than 30 weeks gestation with histological chorioamnionitis. Am J Perinatol 2005; 22: 155-9.

12. Kent A, Dahlstrom JE. Chorioamnionitis/funisitis and the development of bronchopulmonary dysplasia. J Paediatr. Child Health. 2004; 40: 356-9.

13. Redline RW, Wilson-Costello D, Hack M. Placental and Other Perinatal Risk Factors for Chronic Lung Disease in Very Low Birth Weight Infants. Pediatric Research. 2002; 52: 713-18.

14. Van Marter LJ, Dammann O, Allred EN et al. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in pretem infants. J Pediatr 2002; 140: 171-6.

15. Lyon AJ, McColm J, Middlemist L, et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998; 78: F10-F14.

16a. Lahra MM, Beeby PJ, Jeffery HE. Maternal versus fetal inflammation and respiratory distress syndrome: a 10 year hospital cohort study. Arch Dis Child Fetal Neonatal Ed. 2008;

16b. Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis and chronic lung disease: a 13 year hospital cohort study. 2008; Submitted for publication.

17. Henderson-Smart D, Hutchinson JL, Donoghue DA, et al. Prenatal predictors of chronic lung disease in very preterm infants. Arch Dis Child Neonatal Ed 2006; 91: F40-F45.

18. Lal MK, Manktelow BN. Draper ES, Field DJ. Chronic lung disease of prematurity and intrauterine growth retardation: A population-based study. Pediatrics 2003; 111: 483-487.

19. Todd DA, Jana A, John E. Chronic oxygen dependency in infants born at 24-32 weeks’ gestation: the role of antenatal and neonatal factors. J Paediatr Child Health 1997; 33: 402-407.

19a. Bjorklund L, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatric Res. 1997; 42: 348-355.

19b. Wada K, Jobe A, Ikegami M. Tidal volume effects on surfactant treatment responses with the initiation of ventilation in preterm lambs. J Appl Physiol. 1997; 83: 1054-1061.

20. Gannon CM, Wiswell TE, Spitzer AR. Volutrauma, PaCO2 levels, and neurodevelopmental sequelae following assisted ventilation. Clin Perinatol. 1998; 25: 159-175.

21. Van Marter LJ, Allred EN, Pagano M, et al Do clinical markers of barotraumas and oxygen toxicity explain inter-hospital variation in rates of chronic lung disease? Pediatrics. 2000; 105: 1194-1201.

22. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset Ssepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network. Pediatrics, 2002; 110: 285-291.

23. Ogihara T, Okamoto R, Kim HS, et al New evidence for the involvement of oxygen radicals in triggering neonatal chromic lung disease. Pediatric Research. 1996; 39: 117-119.

24. Saugstad OD. Is oxygen more toxic than currently believed? Pediatrics. 2001; 108: 1203-1205.

25. Marshall DD, Kotelchuck M, Young T, et al. Risk Factors for Chronic Lung Disease in the Surfactant Era: A North Carolina Population-based Study of Very Low Birth Weight Infants. Pediatrics 1999; 104: 1345-1350.

26. Gonzalez A, Sosenko IR, Chandar J, et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatrics 1996; 128: 470-478.

27. Rojas MA, Gonzalez A, Bancalari E et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatrics 1995; 126: 605-610.

28. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews 2002, issue 3. Art. No.: CD000174

29. Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database of Systematic Reviews 2003, issue 1. Art. No.: CD003745

30. 30. Mosalli R, AlFaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of morbidity and mortality in extremely low birth weight infants. Cochrane Database of Systematic Reviews 2008, issue 1. Art. No.: CD006181

31. Mikity-VG; Taber-P. Complications in the treatment of the respiratory distress syndrome. Bronchopulmonary dysplasia, oxygen toxicity, and the Wilson-Mikity syndrome. Pediatr Clin North Am. 1973 20: 419-31.

32. Bhutani VK, Abbasi S. Long term pulmonary consequences in survivors with bronchopulmonary dysplasia. Clin Perinatol. 1998; 19: 649-671.

33. Doyle LW. Chavasse R. Ford GW. Olinsky A. Davis NM. Callanan C. Changes in lung function between age 8 and 14 years in children with birth weight of less than 1,501 g. Pediatric Pulmonology. 1999; 27: 185-90.

34. Valleur Masson D, Vodovar M, Zeller J, Laudat F, Masson Y, Kassis M, Nobre R, Kochert F, Voyer M. Bronchopulmonary dysplasia. Course over 3 years in 88 children born between 1984 and 1988. Arch Fr Pediatr. 1993; 50: 553-9.

35. Landry SH, Fletcher JM, Denson SE, Chapieski ML. Longitudinal outcome for low birth weight infants: effects of intraventricular hemorrhage and bronchopulmonary dysplasia. J Clin Exp Neuropsychol. 1993; 15: 205-18.

36. Vohr BR, Coll CG, Lobato D, Yunis KA, O'Dea C, Oh W. Neurodevelopmental and medical status of low-birthweight survivors of bronchopulmonary dysplasia at 10 to 12 years of age. Dev Med Child Neurol. 1991; 33: 690-7.

37. Luchi JM, Bennett FC, Jackson JC. Predictors of neurodevelopmental outcome following bronchopulmonary dysplasia. Am J Dis Child. 1991; 145: 813-7.

38. Williamson WD, Wilson GS, Lifschitz MH, Thurber SA. Nonhandicapped very-low-birth- weight infants at one year of age: developmental profile. Pediatrics. 1990; 85: 405-10.

39. Gray PH, Burns YR, Mohay HA, O'Callaghan MJ, Tudehope DI. Neurodevelopmental outcome of preterm infants with bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed. 1995; 73: F128-34.

40. Robertson CM, Etches PC, Goldson E, Kyle JM. Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. Pediatrics. 1992; 89: 365-72.

41. Majnemer A. Riley P. Shevell M. Birnbaum R. Greenstone H. Coates AL. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Developmental Medicine & Child Neurology. 2000; 42: 53-60.

42. Palta M. Sadek-Badawi M. Evans M. Weinstein MR. McGuinnes G. Functional assessment of a multicenter very low-birth-weight cohort at age 5 years. Newborn Lung Project. Archives of Pediatrics & Adolescent Medicine. 2000; 154: 23-30.

43. Hughes CA. O'Gorman LA. Shyr Y. Schork MA. Bozynski ME. McCormick MC. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. Journal of Developmental & Behavioral Pediatrics. 1999; 20: 1-8.

44. Gregoire MC. Lefebvre F. Glorieux J. Health and developmental outcomes at 18 months in very preterm infants with bronchopulmonary dysplasia. Pediatrics. 1998; 101: 856-60.

45. Singer L. Yamashita T. Lilien L. Collin M. Baley J. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics. 1997; 100: 987-93.

46. Davis P, Thorpe K, Roberts R, et al. Evaluating "old" definitions for the "new" bronchopulmonary dysplasia (BPD). Pediatric Research. 2001; 49: 27A.

47. Schindler MB. Strategies to prevent chronic neonatal lung disease. J Paediatr Child Health 1996; 32: 477-479.

48. Sharek PJ, Baker R, Litman F, et al. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. Pediatrics. 2003; 111: e426-e431

49. Burch K, Rhine W, Baker R, et al. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics. 2003; 111: e432-e436.

50. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004454

51. Figueras-Aloy J, Serrano MM, Rodriguez JP, et al Antenatal glucocorticoid treatment decreases mortality and chronic lung disease in survivors among 23-28 week gestational age preterm infants. Am J Perinatology. 2005; 22: 441-448.

52. Stevens TP, Blennow M, Myers EW, Soll R. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003063

53. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 1999, Issue 4. Art. No.: CD001456

54. Ehrenkranz RA, Mercurio MR. Bronchopulmonary dysplasia. In: Effective care of the newborn infant. Eds: Sinclair JC and Bracken MB. Oxford University Press 1992; 18; 399-424.

55. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD000503

56. Osborn DA, Evans N. Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD002055

57. Garland JS, Buck RK, Allred EN, Leviton A. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. Arch Pediatr Adolesc Med. 1995; 149: 617-22.

58. Woodgate PG, Davies MW. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD002061

60. Kamlin COF, Davis PG. Long versus short inspiratory times in neonates receiving mechanical ventilation. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004503

61. Greenough A, Dimitriou G, Prendergast M, Milner AD. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD000456

62. Henderson-Smart DJ, Cools F, Bhuta T, Offringa M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD000104

63. Bhuta T, Henderson-Smart DJ. Rescue high frequency oscillatory ventilation versus conventional ventilation for pulmonary dysfunction in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000438

64. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000; 105: 295-310.

65. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-Saturation Targets and Outcomes in Extremely Preterm Infants NEJM. 2003; 349: 959-967.

66. Bhuta T, Henderson-Smart DJ. Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000328

67. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD001968

68. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD000501

69. Watterberg, KL,Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics. 1995; 95: 120-125.

70. Watterberg KL, Gerdes KL, Gifford L, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999; 104: 1258-1263.

71. Watterberg KL, the PROPHET study group. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: A multicenter trial. Pediatrics. 2004; 114: 1649-1657.

72. Rademaker KL, de Vries LS, Uiterwaal CS, et al. Postnatal hydrocortisone treatmentfor chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal Ed. 2008; 93: 58-63.

73. Watterberg KL, the PROPHET study group. Long term outcomes of extremely low birth weight infants treated with early low dose hydrocortisone to prevent bronchopulmonary dysplasia. Pediatric Academic Societies Spring meeting, 2006; Abstract 2755.4.

74. AAP. Committee on Fetus and Newborn. Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm Infants. Pediatrics 2002; 109: 330-338.

75. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease. Pediatrics. 2005; 115: 655-651.

76. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, the DART Study investigators. Low-dose dexamethasone facilitated extubation among chronically ventilator-dependent infants: A Multicenter, International, Randomized Controlled Trial. Pediatrics. 2006; 117: 75-83.

77. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001146

78. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001144

79. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001145

80. Wilson DM, Baldwin RB, Ariagno RL. A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr. 1988; 113: 764-8.

81. Cronin CM, Dean H, MacDonald NT, Seshia. MM Basal and post-ACTH cortisol levels in preterm infants following treatment with dexamethasone. Clin Invest Med. 1993; 16: 8-14.

82. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD000509

83. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD001969

84. Lister P, Iles R, Shaw B, Ducharme F. Inhaled steroids for neonatal chronic lung disease. Cochrane Database of Systematic Reviews 1999, Issue 4. Art. No.: CD002311.

85. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD002057

86. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD001817

87. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001453

88. Ng GYT, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD003214

89. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review: Withdrawn). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.

15. Разработчики:

Дата добавления: 2015-09-18 | Просмотры: 351 | Нарушение авторских прав